key: cord-0766660-lrruv02h
authors: Argun Baris, Serap; Oksuzler, Gozde; Boyaci, Hasim; Basyigit, Ilknur
title: Fiberoptic bronchoscopy via intubation box during COVID‐19 pandemic
date: 2021-03-02
journal: J Surg Oncol
DOI: 10.1002/jso.26431
sha: 2b2f83e616e78e441e898072982eb916a5534896
doc_id: 766660
cord_uid: lrruv02h

nan

patients has been shown to have a high viral load, especially in the nose, throat, and trachea. 3, 4 In our clinic, bronchoscopy has been performed via intubation box for protecting the bronchoscopy team from aerolization risk from the early days of the pandemic to day and we want to share our experiences of fiberoptic bronchoscopy procedure during the first wave of COVID-19 pandemic.

The first COVID-19 case occurred on March 10, 2020 in our country. Bronchoscopy appointments were postponed during the first 2 weeks of the pandemic in our clinic due to the high transmission risk of this unpredictable virus. However, to prevent delay in diagnosis especially in malignancy suspected patients, the bronchoscopy procedure was started on April 1 by providing appropriate conditions and using personal protective equipment (PPE) including a face shield, gown, gloves, and N-95 respirators.

Asymptomatic cases are an important challenge for the risk of transmitting to other individuals and healthcare workers, although they appear healthy. According to the CHEST/AABIP Guideline and Expert Panel Report, it is recommended to test for COVID-19 infection before bronchoscopy, even if the patient is asymptomatic. It is recommended to perform procedures using PPEs in patients with negative test results before bronchoscopy. 3 In our study, all patients were questioned for COVID-19 symptoms and undergone polymerase chain reaction (PCR) test for COVID-19 before bronchoscopy and all of them were negative for COVID-19.

There is a decrease in cancer screening, diagnosis, and treatment period during the first months of the pandemic related to travel restrictions, postponements of routine controls or diagnostic procedures, the anxiety of transmission risk in both patients and healthcare workers. 5, 6 According to the CHEST/AABIP Guideline and Expert Panel Report, it is recommended that bronchoscopy should be performed in a timely and safe manner for both diagnosis and staging indication in cases with suspected lung cancer. 3 In our clinic, bronchoscopy has been performed since the first weeks of the pandemic to prevent diagnosis delay, especially in malignant patients. And malignancy was the most common indication for bronchoscopy (69.3%).

As known, premedication of bronchoscopy includes nebulized lidocaine but nebulization itself is an aerosol-generating procedure.

So nebulized lidocaine administration is not recommended for premedication because it increases the risk of aerolization. 7 We did not use nebulized lidocaine in our clinic. Only intranasal or intraoral lidocaine was applied for topical anesthesia and to minimize cough.

Sedation was achieved by applying midazolam intravenous 2-3 mg before the procedure.

should be performed in a negative pressure room with a reduced number of staff in the bronchoscopy team to minimize the risk of transmission. 7, 8 No observers, students, or trainees should be in the bronchoscopy area. 8 The procedure should be performed in the shortest time and with the least number of sampling procedures necessary to achieve the clinical goal. 7 In our clinic, bronchoscopy was performed by an experienced pulmonologist and bronchoscopy nurse. The mean duration of the procedure was nearly 5 min during bronchial lavage while it was approximately 10-15 min in mucosa biopsy, fine needle aspiration, or bronchoalveolar lavage procedures.

The COVID-19 outbreak has led to the development of various devices (intubation box, aerosol box, and surgical tent) and alternative searches to protect healthcare workers from the risk of contamination during tracheal intubation or procedures with a risk of aerolization such as bronchoscopy. 9,10 Since we did not have a negative pressure room, bronchoscopy was performed via intubation box during bronchoscopy for protecting the bronchoscopy team from aerolization risk in a well-ventilated room (Figure 1 ). The intubation box was cleaned with a disinfectant containing 80% alcohol, and UV sterilization was applied 15 min after each patient.

Between April 1 and June 15, 49 patients underwent diagnostic fiberoptic bronchoscopy. There were 38 men (77.6%) and 11 women (22.4%). The mean age of the patients was 59.02 ± 12.6 years. The most common indication for bronchoscopy was malignancy (69.3%), followed by infections including tuberculosis and pneumonia (18.4%).

Twenty-eight percent of the cases had normal bronchoscopic findings while bronchoscopic findings suggest malignancy (endobronchial

Bronchoscopic procedures during COVID-19 pandemic: experiences in Turkey

Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations

The use of bronchoscopy during the COVID-19 pandemic: CHEST/AABIP guideline and expert panel report

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic

Cancer treatment and research during the COVID-19 pandemic: experience of the first 6 months

Safe performance of diagnostic bronchoscopy/EBUS during the SARS-CoV-2 pandemic

Performing bronchoscopy in times of the COVID-19 pandemic: practice statement from an international expert panel

The aerosol box for intubation in coronavirus disease 2019 patients: an in-situ simulation crossover study

Pediatric laryngoscopy and bronchoscopy during the COVID-19 pandemic: a four-center collaborative protocol to improve safety with perioperative management strategies and creation of a surgical tent with disposable drapes